SWOG clinical trial number
S9918

A Phase II Study of Daunomycin and Ara-C Given by Continuous IV Infusion with PSC-833 for Previously Untreated Non-M3 Acute Myeloid Leukemia (AML) in Patients of Age 56 or Older

Closed
Phase
Accrual
29%
Abbreviated Title
Elderly AML
Activated
02/01/2000
Closed
03/15/2001
Participants
NCORP, Members, Pathologists

Research committees

Leukemia

Treatment

Cytosine Arabinoside Daunomycin Filgrastim PSC833

Eligibility Criteria Expand/Collapse

Must have morphologically confirmed diagnosis of previously untreated non-M3 AML; > / = 56 years of age, Zubrod PS 0-3.

Publication Information Expand/Collapse

2017

Prognostic methylation markers for survival in cytogenetically normal AML patients treated on SWOG trials

X Qu;M Othus;J Davison;Y Wu;L Yan;E Estey;J Radich;H Erba;F Appelbaum;M Fang Cancer Jul 1;123(13):2472-2481; 2017 Feb 21[Epub ahead of print]

PMid: PMID28222251; PMC5705230

2015

Resistance prediction in AML: analysis of 4,601 patients from MRC/NCRI, HOVON/SAKK, SWOG, and MD Anderson Cancer Center

R Walter;M Othus;AK Burnett;B Lowenberg;H Kantarjian;G Ossenkoppele;R Hills;F Ravandi;A Evans;SA Pierce;F Appelbaum;E Estey Leukemia 29(2):312-320

PMid: PMID25113226 | PMC number: PMC4318722

Cytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia

B Medeiros;M Othus;M Fang;F Appelbaum;H Erba Haematololgica Mar;100(3):331-335

PMid: PMID25527568 | PMC number: PMC4349271

Prognostic methylation markers for survival in cytogenetically normal AML patients treated on SWOG trials

X Qu;M Othus;J Davison;L Yan;E Estey;J Radich;H Erba;F Appelbaum;M Fang Blood 126(23):688; American Society of Hematology Annual Meeting (Dec 5-8, 2015, Orlando, FL), oral presentation;

2014

Unsuccessful cytogenetic analysis is a poor prognostic feature in acute myeloid leukemia

B Medeiros;M Othus;E Estey;M Fang;F Appelbaum British Journal of Haematology 28(2):245-250;

PMid: PMID24383844 | PMC number: PMC4117470

Declining rates of treatment-related mortality in patients with newly-diagnosed AML given "intense" induction regimens: a report from SWOG and MD Anderson

M Othus;H Kantarjian;S Petersdorf;F Ravandi;J Godwin;J Cortes;S Pierce;H Erba;S Faderl;F Appelbaum;E Estey Leukemia 28(2):289-292;

PMid: PMID23760400 | PMC number: PMC4457325

2013

Significance of FAB subclassification of "acute myeloid leukemia, not otherwise specified" in the 2008 WHO classification: analysis of 5,848 newly diagnosed patients

RB Walter;M Othus;A Burnett;B Lowenberg;H Kantarjian;GJ Ossenkoppele;RK Hills;K van Montfort;F Ravandi;A Evans;SA Pierce;F Appelbaum;EH Estey Blood 121(13):2424-2431;

PMid: PMID23325837 | PMC number: PMC3612855

Prediction of therapeutic resistance in adult acute myeloid leukemia: analysis of 4,550 newly diagnosed patients from MRC/NCRI, HOVON, SWOG, and MD Anderson Cancer Center

R Walter;M Othus;AK Burnett;AK Burnett;B Lowenberg;H Kantarjian;GJ Ossenkoppele;RK Hills;F Ravandi;A Evans;SA Pierce;F Appelbaum;E Estey Blood 122:64; American Society of Hematology annual meeting (Dec 7-10, 2013), oral;

2012

Impact of residual normal metaphases in core binding factor acute myeloid leukemia

B Medeiros;M Othus;M Fang;F Appelbaum;E Estey Cancer 118(9):2420-2423;

PMid: PMID21928314 | PMC number: PMC3490403

Impact of body-mass index in the outcome of adult patients with acute myeloid leukemia

B Medeiros;M Othus;EH Estey;M Fang;F Appelbaum Haematologica 97(9):1401-1404

PMid: PMID22315487 | PMC number: PMCID3436242

Declining rates of treatment-related mortality recent in patients with newly-diagnosed AML given "intense" induction regimens: a report from SWOG and MD Anderson

M Othus;H Kantarjian;S Petersdorf;F Ravandi;J Godwin;J Cortes;S Pierce;H Erba;S Faderl;F Appelbaum;E Estey Blood 120(21):abst. 129; American Society of Hematology Annual Meeting, oral;

2011

Influence of residual normal metaphases in acute myeloid leukemia patients with monosomal karyotype [PMID21330329; PMC3069244]

B Xie;M Othus;B Medeiros;M Fang;F Appelbaum;E Estey Haematologica 96(4):631-632

Cytarabine dose for acute myeloid leukemia. (Letter to the Editor) [PMID21631340]

B Medeiros;M Othus;F Appelbaum New England Journal of Medicine 364(11):2167-2168

Prognostic import of French-American-British (FAB) system as embedded in 2008 revision of World Health Organization classification of AML

L Newell;M Othus;R Walter;E Petersdorf;T Chauncey;JE Anderson;JE Godwin;K Kopecky;F Appelbaum;E Estey Blood 118(21):abstract 1446; American Society of Hematology, poster presentation;

Prediction of early death following induction therapy for newly diagnosed acute leukemia with pretreatment risk scores: a novel paradigm for treatment assignment

R Walter;M Othus;G Borthakur;F Ravandi;J Cortes;S Pierce;F Appelbaum;H Kantarjian;E Estey Journal of Clinical Oncology, 29(33):4417-23;

PMid: PMID21969499 | PMC number: PMC3221524

2010

The effect of complete remission (CR) and CR with incomplete platelet recovery (CRp) on outcome in acute myeloid leukemia: a combined eastern cooperative oncology group (ECOG), Southwest Oncology Group (SWOG), and M.D. Anderson Cancer Center study

Journal of Clinical Oncology 28(10):1766-1771;

Prognostic impact of monosomal karyotype in young adults and elderly acute myeloid leukemia: the Southwest Oncology Group experience [PMID: 20562328; NIHMSID244631]

BC Medeiros;M Othus;M Fang;D Roulston;FR Appelbaum Blood 116(13):2224-2228

PMid: PMID20562328 | PMC number: PMC3709629

Influence of residual normal metaphases in patients with monosomal karyotype

B Xie;M Othus;B Medeiros;M Fang;F Appelbaum;E Estey Blood 116:Abstract 1671; ASH 2010 meeting; poster presentation